Phosphorothioate oligonucleotides were identified which directly inhibited human type II phospholipase A 2 (PLA 2 ) enzyme activity in a sequence specific manner. The minimum pharmacophore common to all oligonucleotides which inhibited PLA 2 enzyme activity consisted of two sets of three or more consecutive guanosine residues in a row. These oligonucleotides appear to form G quartets resulting in the formation of oligonucleotide aggregates. Additionally, a phosphorothioate backbone was required to be effective inhibitors of type II PLA 2 . The activity of one oligodeoxynucleotide, IP 3196 (5'-GGGTGGGTATAG-AAGGGCTCC-3) has been characterized in more detail. IP 3196 inhibited PLA 2 enzyme activity when the substrate was presented in the form of a phospholipid bilayer but not when presented in the form of a mixed micelle with anionic detergents. Human type II PLA 2 was 50-fold more sensitive to inhibition by IP 3196 than venom and pancreatic type I enzymes. These data demonstrate that phosphorothioate oligonucleotides can specifically inhibit human type II PLA 2 enzyme activity in a sequence specific manner.
INTRODUCTION
Metabolites of arachidonic acid such as prostaglandins and leukotrienes are potent, short lived biological mediators, many of which exhibit pro-inflammatory activity. The major pool of arachidonic acid in the cell is esterified to the sn-2 position of membrane lipids, with the pool of free arachidonic acid available for metabolism by cyclo-oxygenase and lipoxygenases relatively low. Thus, release of arachidonic acid from membrane lipids is the first obligatory step in the synthesis of prostaglandins and leukotrienes. Although there are multiple biochemical pathways for liberation of arachidonic acid from membrane lipids, phospholipase A 2 (PLA 2 ) mediated hydrolysis of fatty acids is the most direct pam (1) .
Phospholipases A 2 (EC 3.1.1.4) are a family of lipolytic enzymes that hydrolyze the sn-2 bond of membrane phospholipids (2, 3) . Low molecular weight (14 to 30 kDa) PLA 2 enzymes have been purified from extracellular sources such as pancreatic secretions, inflammatory exudates, snake and insect venoms. The secreted, low molecular weight PLA 2 enzymes may be grouped into three different families based upon sequence and disulfide bond patterns. (4) (5) (6) . Examples of type I enzymes include PLA 2 secreted in mammalian pancreatic fluid and lung (pancreatic PLA 2 ) and PLA 2 isolated from venoms of Elapidae (cobras) and Hydrophidae (sea snakes). Type II enzymes are represented by a PLA 2 secreted from mammalian cells in response to inflammatory mediators and PLA 2 enzymes isolated from venoms of Viperidae (old world vipers) and Crotalidae (rattlesnakes and pit vipers). PLA 2 isolated from bee venom exhibits limited sequence similarity to type I and II enzymes and has been classified as a type IE enzyme (5) . In addition, a high molecular weight cytosolic PLA 2 has been characterized which does not share sequence similarity with the low molecular weight secreted enzymes (6) (7) (8) . The high molecular weight enzyme is not strictly a PLA 2 enzyme in that it also exhibits lysophospholipase and transacylase activities (9, 10) . Biochemical and genetic evidence suggest that additional forms of PLA 2 may exist in mammalian tissues (11 -16) . Although the data remains controversial, it would appear that no single form of PLA 2 is exclusively responsible for arachidonic acid liberation (17) (18) (19) (20) (21) (22) (23) (24) . The involvement of different types of PLA 2 may be dependent upon the stimulus responsible for activating PLA 2 , the cell type from which arachidonic acid is derived and the phospholipid pool from which arachidonic acid is liberated (24) (25) (26) .
mediates arachidonic acid release but may directly damage host cells due to excessive hydrolysis of membrane lipids.
Because phospholipase A2 has been implicated in generating the arachidonic acid substrate for cyclo-oxygenases and lipoxygenases and perhaps directly damaging cells, major research programs have been devoted towards the identification of inhibitors of PLA 2 , with limited success. Oligonucleotides represent a chemical class of agents whose effects on this family of enzymes have not been studied. Our initial approach was to design oligonucleotides to inhibit human type II PLA 2 expression by an antisense mechanism (34) . A number of oligonucleotides were designed to hybridize to human type II PLA2 mRNA and were demonstrated to reduced type II PLA 2 enzyme activity from cytokine activated A431 cells. In characterizing the mechanism by which the oligonucleotides inhibited type II PLA 2 expression it was discovered that in addition to inhibition of type II PLA 2 expression by an antisense mechanism, a subset of the active oligonucleotides directly inhibited type II PLA 2 enzyme activity. The structural and chemical requirements for oligonucleotide inhibition of type II PLA 2 are described.
MATERIAL and METHODS
Purification of PLA 2 enzymes Human type II PLA 2 was partially purified (approximately 20-fold) from A431 conditioned serum free medium (Opti-MEM, Gibco, Grand Island, NY) by ion exchange chromatography using a Mono S column (Pharmacia, Upsalla, Sweden). Previous experiments have demonstrated that A431 cells secrete a type II PLA 2 into the culture supernatant. The identification of the enzyme as a type II PLA 2 was based upon substrate specificity and calcium requirements as defined by Kramer et al. (35) . Analysis of the Mono S purified PLA 2 by reverse phase HPLC and gel filtration chromatography revealed a single peak of enzyme activity in each case (Chiang and Bennett, manuscript in preparation). This enzyme activity was recognized by monoclonal antibodies specific for type II PLA 2 (Chiang and Bennett, manuscript in preparation) but not by antibodies which recognize type I pancreatic PLA 2 (36) . Furthermore, analysis of RNA from A431 cells by northern blot and polymerase chain reaction demonstrated the presence of type II PLA 2 transcripts, but not type I PLA 2 transcripts (data not shown). Thus, these data in aggregate, strongly suggest that the only PLA 2 released into the medium of A431 cells is a type II enzyme.
Alternatively, human type II PLA 2 cloned from human placental cDNA was expressed in a baculovirus expression system as previously described (Chiang and Bennett, manuscript in preparation) and purified by chromatography on a S-Sepharose column followed by a heparin Sepharose column and finally reverse phase HPLC using a C4 column, resulting in approximately 1000-fold purification. The purified enzyme was approximately 70% pure at this stage.
Purified bovine pancreatic PLA 2 , Apis mellifera PLA 2 , Naja naja naja PLA 2 , and Crotalus durissus terrifiicus PLA 2 were obtained from Sigma Chemical Co (St. Louis, MO). PLA 2 isolated from the venom of Trimeresurus flavoviridis was purchased from Calbiochem (La Jolla, CA). PLA 2 was partially purified from Agkistrodon pisdvorus piscivirus venom (Sigma Chemical Co.) by chromatography on a Mono S column.
Oligonucleotide synthesis
Phosphorothioate and phosphodiester oligonucleotides were synthesized as previous described (37) . 2'-O-methyl and 2'-Opropyl oligonucleotides were synthesized as described (37, 38) . 2'-fluoro oligonucleotides were prepared as described by Kawasaki et al. (39) . After cleavage from controlled pore glass resign, protecting groups were removed by incubation in concentrated ammonium hydroxide at 55 °C. The oligonucleotides were precipitated twice from 0.5 M NaCl solution with 2.5 volumes ethanol. In some cases oligonucleotides were further purified by reversed phase high pressure chromatography using (40) . The reaction mixture consisted of 100,000 cpm of [ 3 H]-oleic-acidlabeled, autoclaved E.coli, 100 mM Tris (pH = 7.5) and 1 mM CaCl 2 in a final volume of 200 fiL. The reactions were performed at 37°C and the times adjusted to give between 7.5 % and 20% hydrolysis of substrate lipid (generally 15 to 30 minutes). The reactions were terminated by the addition of 100 liL of 2 M HC1 followed by 100 /*L of 20 mg/ml fatty acid free bovine serum albumin. The tubes were vortexed and centrifuged at 14,000 xg for 5 min to remove bacteria. ]-arachidonic acid released quantitated by thin layer chromatography as previously described (41) . PLA 2 assays using deoxycholate/l-palmitoyl-2-[
14 C]-arachidonyl phosphatidylethanolamine mixed micelles were performed as previously described (41) .
Gel filtration chromatography
Different molecular forms of the oligonucleotides were resolved by gel filtration chromatography using a Superdex 75 HR10/30 column (Pharmacia, Upsalla, Sweden) equilibrated with 10 mM potassium phosphate (pH = 7.2), 50 mM KC1. The flow rate was 0.5 ml/min. Elution of oligonucleotides from the column was monitored by the absorbance at 260 nm.
RESULTS

Sequence specific inhibition of human type II PLA 2 by phosphorothioate oligonucleotides
While characterizing the mechanism of action of several phosphorothioate oligodeoxyribonucieotides which were designed to inhibit type n PLA 2 expression by an antisense mechanism, it was discovered that a subset of oligonucleotides directly inhibited human type II PLA 2 enzyme activity. As an example IP 3196 inhibited human type II PLA 2 enzyme activity with an IC 50 value between 0.25 and 0.5 /iM, while an unrelated phosphorothioate oligodeoxyribonucleotide, IP 1573, failed to inhibit enzyme activity at a 20-fold higher concentration ( Fig.  1 , Table 1 ). In an attempt to identify a sequence motif responsible for the inhibition of PLA 2 , a number of phosphorothioate oligodeoxyribonucieotides were tested for their ability to directly inhibit human type II PLA 2 (Table 1) . Although, most phosphorothioate oligodeoxyribonucieotides slightly inhibited type II PLA 2 enzyme activity at a concentration of 1 fiM, those sharing at least two sets of guanosine residues three or more bases in length inhibited expression by greater than 50% at 1 pM (Table  1) . Oligonucleotides with two guanosine residues in a row repeated several times (i.e. 4745 and 4646) were not effective inhibitors of type II PLA 2 . In general, the inhibitory activity correlated with the number of guanosine residues in the repeats.
Identification of the minimal sequence which inhibits PLA 2 Bases were selectively deleted or changed from oligonucleotides IP 3196 and IP 4015 to identify the minimum sequence required for inhibition of human type II PLA 2 enzyme activity. IP 4015 is a 20 base phosphorothioate deoxyoligonucleotide with 2 sets of guanosine quartets at the 3'-end of the oligonucleotide ( Table  2 ). Deletion of two guanosines from the 3'-end of IP 4015 resulted in a marked loss of activity (Table 2 ). However, all the bases 5' to the guanosine runs could be deleted (i.e. IP 4717) without markedly affecting inhibitory activity of the oligonucleotide ( Table 2 ). The sequence TGGGG inhibited type II PLA 2 by 50 % at 1 nM concentration while the sequence GGGG failed to inhibit type II PLA 2 ( Table 2) .
IP 3196 is a 21 base phosphorothioate deoxyoligonucleotide which contains three sets of guanosine repeats, each three bases in length ( Table 2 ). Deletion of 9 bases from the 3'-end of the oligonucleotide, including 1 of the three sets of guanosine runs, did not significantly affect the inhibitory effects of the oligonucleotides ( Table 2) . Deletion of the first 3 guanosine residues from the 5'-end of the oligonucleotide failed to significantly affect the inhibitory activity of the oligonucleotide. However, if six bases were deleted from the 5'-end of the oligonucleotide, inhibitory activity was lost (Table 2) . Thus, if two out of the three sets of guanosine runs were deleted the (Fig. 3) . Purification of IP 3196 by reversed phase HPLC would be expected to denature G-quartet structures by removing the monovalent cation. When purified by reversed phase HPLC, IP 3196 elutes as one predominant peak at a retention time expected for a 21-mer phosphorothioate oligonucleotide (based upon the retention time of phosphorothioate standards). After the oligonucleotide was incubated for 16 hr in buffer containing 100 mM KC1, most of the oligonucleotide eluted at shorter retention times indicative of multimeric complexes (Fig. 3b) . The major peak eluted at a retention time consistent with a dimer. Incubation in 100 mM NaCl also resulted in formation of multimeric Analysis of IP 3196 by gel filtration chromatography. IP 3196 purified by reverse phase HPLC chromatography was incubated with either water (a) or 100 mM 100 mM KC1 (b) for 16 hours at 25°C or 100 mM KC1 for 16 hr followed by incubation with 1 % deoxycholate and 1 mM CaCl 2 for 30 minutes at 37°C (c) prior analysis by gel filtration chromatography. Samples were applied to a Superdex 75 HR 10/30 column equilibrated with 10 mM potassium phosphate; pH = 7.2, 50 mM KC1, and eluted at a flow rate of 0.5 ml/min. complexes, however, approximately 50% of the oligonucleotide remained as monomer (data not shown). It has been reported that potassium preferentially stabilizes G-quartet structures relative to sodium (42) .
Inhibition of type II PLA 2 correlated with the extent of aggregation of the oligonucleotide (Fig. 4) . HPLC purified IP 3196 incubated with 100 mM potassium for 16 hours was a more effective inhibitor of human type II PLA 2 than oligonucleotide incubated in the absence of monovalent cation. Addition of equivalent amount of NaCl or KC1 to the PLA 2 enzyme reaction did not affect the enzyme activity (data not shown). In addition, analysis of fractions of IP 3196 separated by gel filtration chromatography revealed that higher molecular weight species were more effective inhibitors than monomers (data not shown). Although the structure of the aggregate species have not been further characterized, the sequence of the oligonucleotides and the retention times of the aggregates suggest that these species are dimeric or tetrameric structures stabilized by G-quartets.
IP 3196 inhibited human type II PLA 2 enzyme activity when the substrate was presented in the form of an organized bilayer such as E.coli membranes or phosphatidylethanolamine/phosphatidylcholine (PE/PC) liposomes. IP 3196 failed to inhibit type II PLA 2 if the substrate, PE, were presented to the enzyme in (Fig. 3c) . Thus, deoxycholate changes the aggregation state of IP 3196.
To address whether the enzyme was binding to the substrate as a potential mechanism of inhibition, 32 P-labeled 3196 and an inactive phosphorothioate oligonucleotide (IP 3481) were incubated with autoclaved E.coli substrate at a concentration of 1 ftM. Both oligonucleotides were found to bind to E.coli substrate (54% for IP 3196 and 73% for IP 3481), thus IP 3196 does not appear to preferentially interact with E.coli substrate. It is not unexpected that phosphorothioate oligonucleotides interact with cellular membranes based upon previous data with mammalian cells (43, 44) .
Detailed analysis of the enzyme kinetics for PLA 2 are complicated because the enzyme hydolyzes acyl bonds at the lipidwater interface of a substrate which is in an aggregated state (2, 6) . In an attempt to characterize the mechanism of inhibition by IP 3196, purified type II PLA 2 from Crotalus durissus terrifitcus venom was incubated with increasing concentrations of 14 C-PE/PC lipid vesicles in the presence of IP 3196. The 14 C-PE/PC lipid vesicles were used because they are a better defined substrate than E.coli membranes. Incubation of purified Crotalus durissus PLA 2 with increasing concentrations of PE/PC vesicles resulted in an apparent saturation of enzyme by the substrate (Fig. 5) . However, under these conditions we were unable to achieve substrate concentrations greater than 400 jtM due to the formation of large lipid aggregates instead of lipid vesicles. Double reciprocal plot of the data failed to generate a linear relationship (data not shown) similar to results previously described for this class of enzyme using phospholipid vesicles (45) . Incubation of the enzyme with 0.5 /*M or 5 /iM IP 3196 resulted in apparent exponential substrate saturation curves with a shift in the apparent Km of the enzyme (Fig. 5) . These substrate saturation curves are inconsistent with IP 3196 being a simple competitive, noncompetitive, or uncompetitive inhibitor of PLA 2 .
Chemical requirements for inhibitory activity IP 3196 sequence was synthesized with several nucleotide analogs to further define the pharmacophore required for inhibition of human type II PLA 2 enzyme activity. The phosphodiester analog of IP 3196 failed to inhibit human type II PLA 2 ( Table  4) . Substitution of a methoxy or propoxy group at the 2'-position of the sugar, while retaining the phosphorothioate backbone, increased the inhibitory activity of the oligonucleotide. Substitution of a fluoro group at the 2'-position did not change the inhibitory activity of IP 3196 (Table 4) . Oligonucleotides with these 2' modification and a phosphodiester backbone did not inhibit type II PLA 2 enzyme activity. The lack of activity for oligonucleotides with a phosphodiester backbone was not due to nuclease degradation of the oligonucleotides during the enzyme reactions, as these oligonucleotides were stable for at least 4 hours when incubated in the presence of the cell supernatants used for the PLA 2 assays (data not shown). The PLA 2 enzyme assays were 15 to 30 minutes in length. Nor does the phosphorothioate linkage preferentially promote aggregation of the oligonucleotide into G quartet structures as phosphodiester derivatives were found to readily form similar structures as determined by size exclusion chromatography (data not shown). Thus, the phosphorothioate linkage in the backbone appears to an essential component of the active pharmacophore.
DISCUSSION
It has long been appreciated that proteins may interact with nucleic acids in a sequence specific manner. Well characterized examples of such interactions are binding of transcription factors or restriction endonucleases to specific DNA sequences. Two examples of proteins which unexpectedly bind nucleic acids in a sequence-specific manner are aconitase binding to the iron responsive element and glyceraldehyde-3-phosphate dehydrogenase binding to tRNA (46, 47) . There are also examples of proteins unexpectedly binding to nucleic acids which do not appear to exhibit sequence specificity such as lactate dehydrogenase and glutathione S-transferase (48, 49) . Thus, in addition to sequence specific interaction with nucleic acids by proteins which regulate gene expression, there are several examples of proteins with functions unrelated to nucleic acids that, in fact, bind to nucleic acids.
Telomeres, the structures at the end of linear chromosomes, are composed of repeated DNA sequences bound by associated proteins. The sequences of telomeric DNA repeats in general conform to the consensus sequences d(T/A) 1 _ 4 dG 1 _ 8 (50) . Single stranded oligonucleotides composed of two or more repeats of telomeric consensus sequences adopt a four-stranded structure consisting of Hoogsteen base-paired G-quartets, stabilized by monovalent cations (42, 51, 52) . In addition to specific telomere binding proteins, telomeric-like structures appear to be bound by other unrelated proteins such as vimentin, macrophage scavenger receptor, thrombin, HTV gpl20 protein, a specific nuclease and QUAD (a hepatocyte chromatin protein) (53) (54) (55) (56) (57) (58) (59) . With the exception of HTV gpl20 protein, the proteins listed above bound G-quartet structures containing phosphodiester linkages.
We now describe that phosphorothioate oligonucleotides which also have the capability to form G-quartet structures are selective inhibitors of human type II PLA 2 . Although it was not directly demonstrated that the active pharmacophore was in fact a Gquartet structure, the data are consistent with such a model. The inhibitory activity of the oligonucleotide was lost by denaturing the oligonucleotide prior to addition to the assay. Incubation of RP-HPLC purified oligonucleotide in the presence of potassium ion enhanced the inhibitory activity and also correlated with the appearance of multimeric species as shown by size exclusion chromatography. Finally, oligonucleotide eluting from earlier fractions of a gel filtration column were more potent than later fractions in inhibiting type II PLA 2 .
It should be noted that there are differences in the interaction of specific proteins with G-quartet containing oligonucleotides.
In contrast to what was observed for thrombin and the macrophage scavenger receptor, the oligonucleotides required a phosphorothioate backbone for inhibition of type II PLA 2 . The G-quartet oligonucleotide which inhibited thrombin did not inhibit human type II PLA 2 activity when synthesized with either a phosphodiester or phosphorothioate backbone (Table 1 , and data not shown). Furthermore, the oligonucleotide which bound to HIV gpl20 protein was a relatively weak inhibitor of human type IIPLA 2 (IC5Q > 10 /iM) yet was very effective at inhibiting HTV infection (IC50 = 0.3 /iM). Either the conformation of the Gquartet structure or the loop sequences must confer binding specificity. These studies suggest that although G-quartet containing oligonucleotides can interact with a variety of proteins, these oligonucleotides may form unique structures capable of selectively interacting with different target proteins.
The mechanism of the G-quartet containing phosphorothioate oligonucleotides inhibition of type II PLA 2 enzyme activity is not known. PLA 2 enzyme activity can be inhibited by agents which bind calcium (a required co-factor for the enzyme), by binding to the phospholipid substrate (perturbing the bilayer structure or masking it from the enzyme), or directly binding to the enzyme. It is unlikely that binding to calcium ion was responsible for the inhibitory activity as calcium ion was 1000-fold molar excess over the oligonucleotide and 50-fold molar excess over phosphorothioate groups contributed by the Effect of chemical modification on inhibitory activity of IP 3196. Oligonucleotides were synthesized with either phosphorothioate linkages (P=S) or phosphodiester linkages (P=O) as described in Methods. Oligonucleotides were tested for inhibition of human type II PLA 2 isolated from A431 conditioned serum free medium using [ 3 H]-oleic acid labeled E.coli as a substrate as described in the Methods. oligonucleotide. A reduction in the calcium concentration by 20 to 25 jtM did not significantly change enzyme activity. Although we can not rule out the possibility that interaction with the phospholipid substrate accounts for part of the inhibitory activity of G-quartet containing phosphorothioate oligonucleotides, it is unlikely this is the sole mechanism. Substrate saturation experiments suggest that IP 3196 did not inhibit PLA 2 enzyme activity by competitive, non-competitive or uncompetitive mechanisms. An inhibitory phosphorothioate oligodeoxynucleotide did not preferentially associate with the substrate compared to an inactive oligonucleotide. Furthermore, IP 3196 preferentially inhibited human type II PLA 2 compared to type I PLA 2 from porcine pancreas and venom type I enzymes additional suggest that the oligonucleotide was not masking or perturbing the phospholipid substrate as was the case for lipocortin (40, 60) . More in depth studies are needed to fully characterize the mechanism by which IP 3196 inhibits type H PLA 2 .
The X-ray crystal structure of human type IIPLA 2 reveals the presence of a larger number of positive charged amino acids on the substrate binding surface compared to pancreatic enzyme (61) (62) (63) . In addition the large number of lysine and arginine residues present overall in the human type II enzyme sequence would give it a dominant positive surface potential on the entire surface of the molecule. Thus, it is possible that the anionic Gquartet structure could interact with the substrate binding surface of human type II PLA 2 or other surfaces on the enzyme. The G-quartet structure provides a scaffold to present a high surface density of phosphorothioate groups to the enzyme in a rigid cluster which favors binding to human type II PLA 2 .
There has been much interest in the pharmaceutical industry to identify selective inhibitors of PLA 2 enzymes. These efforts have met with some limited success. Oligonucleotides represent a class of chemical structures which to our knowledge have not been exploited for this class of enzymes. It is possible that oligonucleotide based inhibitors will prove to be selective, potent and non-toxic inhibitors for human type II PLA 2 . Further evaluation of oligonucleotides which directly inhibit PLA 2 enzyme activity as well as those which inhibit PLA 2 expression by an antisense mechanism will determine their potential (23) .
